Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Molecular Templates

NASDAQ MTEM
$1.45 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 22 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

10.17M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
1.14M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.15
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
7.02M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-61.13 %

Upcoming events Molecular Templates

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Molecular Templates

Stock analysis Molecular Templates

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1.01 28.84
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
2.42 4.35
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.19 10.00
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
1.49 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-171.91 7.67

Price change Molecular Templates per year

5.70$ 15.19$
Min Max

Summary analysis Molecular Templates

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Molecular Templates

Revenue and net income Molecular Templates

All parameters

Stock news Molecular Templates

All news
9 March 2023 в 18:40

Molecular Templates Shares Rise 18% After FDA Accepts MT-8421 New Drug App

9 March 2023 в 18:35

Molecular Templates Shares Rise 18% After FDA Accepts MT-8421 New Drug App

30 December 2021 в 21:50

Molecular Templates Shares Climb 28%

30 December 2021 в 21:45

Molecular Templates Shares Climb 28%

18 November 2021 в 16:30

Molecular Templates Gets FDA Fast-Track Designation for MT-6402 >MTEM

18 November 2021 в 16:30

Molecular Templates Gets FDA Fast-Track Designation for MT-6402 >MTEM

About company Molecular Templates

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. is headquartered in Austin, Texas.
Address:
9301 Amberglen Boulevard, Austin, TX, United States, 78729
Company name: Molecular Templates
Issuer ticker: MTEM
ISIN: US6085501095
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2005-02-04
Sector: Healthcare
Industry: Biotechnology
Site: https://www.mtem.com

On which stock exchange are Molecular Templates (MTEM) stocks traded?

Molecular Templates (MTEM) stocks are traded on NASDAQ.

What is the ticker of Molecular Templates stocks (MTEM)?

The stock ticker of Molecular Templates’s stocks or in other words, the code is MTEM. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Molecular Templates (MTEM) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Molecular Templates (MTEM) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Molecular Templates (MTEM) stocks traded?

Molecular Templates (MTEM) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Molecular Templates (MTEM) stocks today?

The current price of Molecular Templates stocks on 20.05.2024 is 1.45 dollars. per share.

What is the dynamics of Molecular Templates (MTEM) stocks from the beginning of the year?

Molecular Templates (MTEM) quotes have increased by -60.97% from the beginning of the year up to 1.45 dollars. per 1 stocks.

How much did Molecular Templates (MTEM) stocks increase in мае 2024?

This month Molecular Templates (MTEM) quotes have increased by -12.12% to 1.45 dollars. per share.

How much are Molecular Templates (MTEM) stocks worth?

Today, on October, 20.05.2024 Molecular Templates’s (MTEM) stocks cost 1.45 dollars..

What is the market capitalization of Molecular Templates (MTEM)?

Capitalization is the market value of Molecular Templates (MTEM) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 20.05.2024, the market capitalization of Molecular Templates (MTEM) is estimated at about 10173003 dollars.